Guardant Health and AnHeart Therapeutics to Develop Guardant360 CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in ROS1-Positive mNSCLC

“We are very excited to partner with Guardant Health, a global leader in oncology companion diagnostics, to identify NSCLC patients with ROS1 fusion mutations who may benefit from taletrectinib. There is a critical need to improve access to high quality diagnostics to help guide treatment decisions for patients,” said Junyuan (Jerry) Wang, Ph.D., chief executive officer of AnHeart Therapeutics. “With our BTD recently granted by FDA, we are committed to advancing taletrectinib for adult patients with advanced or metastatic NSCLC and improving access to convenient biomarker testing in patients who will benefit from our targeted therapy.”

Share:

More News

“Antengene announced it has entered into a global clinical collaboration with MSD to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate (ADC), and MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), Antengene

“Advanced esophageal squamous cell carcinoma is a difficult-to-treat disease, and unfortunately overall survival remains low,” said Marjorie Green, MD, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “The initiation of the pivotal Phase 3 IDeate-Esophageal01 clinical trial demonstrates our shared commitment with Daiichi Sankyo to

“Overall response rate (ORR) was 97% (114/117) with a complete response/stringent complete response (CR/sCR) rate of 68% (79/117) and a very good partial response or higher (>VGPR) rate of 85% (100/117), per International Myeloma Working Group (IMWG) criteria as investigator-assessed. Of those evaluable for minimal residual disease (MRD) testing at

“EMA approval of the MIRACLE trial protocol is a huge milestone for us. Although we’re already seeing recruitment in our first non-EU country, we believe that this expansion into the EU really supercharges our recruitment potential,” said Walter Klemp, Chairman and CEO of Moleculin. “Importantly, when combined with the sites